Profile data is unavailable for this security.
About the company
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
- Revenue in USD (TTM)3.00m
- Net income in USD-131.52m
- Incorporated2016
- Employees128.00
- LocationPrelude Therapeutics Inc175 Innovation BoulevardWILMINGTON 19805United StatesUSA
- Phone+1 (302) 467-1280
- Fax+1 (302) 658-3989
- Websitehttps://preludetx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mural Oncology PLC | 0.00 | -173.30m | 59.97m | 117.00 | -- | 0.2913 | -- | -- | -10.35 | -10.35 | 0.00 | 12.09 | 0.00 | -- | -- | 0.00 | -131.01 | -- | -164.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
| Enzo Biochem Inc | 31.91m | -9.82m | 60.08m | 125.00 | -- | 1.07 | -- | 1.88 | -0.194 | -0.5102 | 0.6268 | 1.07 | 0.3073 | 2.34 | 7.25 | 255,256.00 | -9.46 | -14.58 | -13.74 | -19.56 | 45.86 | 40.43 | -30.77 | -26.20 | 2.55 | -- | 0.0047 | -- | 2.72 | -17.03 | 60.77 | -- | -41.75 | -- |
| Omega Therapeutics Inc | 6.31m | -78.90m | 60.12m | 93.00 | -- | 2.29 | -- | 9.52 | -1.43 | -1.43 | 0.1145 | 0.4762 | 0.0318 | -- | 6.67 | 67,892.48 | -39.72 | -- | -46.68 | -- | -- | -- | -1,249.54 | -- | -- | -- | 0.3917 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
| Bioqual Inc | -100.00bn | -100.00bn | 60.37m | 108.00 | -- | 1.63 | -- | -- | -- | -- | -- | 41.34 | -- | -- | -- | -- | -- | 8.14 | -- | 9.52 | -- | 19.36 | -- | 7.13 | -- | -- | 0.00 | 21.43 | -5.27 | 11.79 | -84.12 | -25.26 | 1.60 | 10.76 |
| Precision BioSciences Inc | 75.10m | 11.48m | 60.62m | 108.00 | 10.97 | 0.9664 | 3.86 | 0.8072 | 0.7641 | 0.0524 | 12.85 | 8.67 | 0.4729 | -- | 29.70 | 688,954.10 | 7.23 | -35.35 | 9.00 | -44.22 | -- | -- | 15.28 | -147.50 | -- | -- | 0.2557 | -- | 94.15 | 34.96 | 41.67 | -- | -32.01 | -- |
| Champions Oncology Inc | 51.66m | -3.40m | 60.83m | 210.00 | -- | -- | -- | 1.18 | -0.2541 | -0.2541 | 3.78 | -0.0244 | 1.88 | -- | 5.75 | 245,976.20 | -12.39 | -10.00 | -44.43 | -23.00 | 44.27 | 46.58 | -6.58 | -6.04 | -- | -- | 333.00 | -- | -6.90 | 13.13 | -36.38 | -- | 0.0479 | -- |
| enVVeno Medical Corp | 0.00 | -21.24m | 61.55m | 31.00 | -- | 1.30 | -- | -- | -1.33 | -1.33 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -54.12 | -58.43 | -57.23 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
| Connect Biopharma Holdings Ltd (ADR) | 24.12m | -21.25m | 61.88m | 81.00 | -- | 0.5602 | -- | 2.57 | -0.3869 | -0.3869 | 0.436 | 2.00 | 0.1826 | -- | -- | 297,728.40 | -16.09 | -66.24 | -17.73 | -71.36 | -- | -- | -88.10 | -- | -- | -- | 0.0029 | -- | -- | -- | 49.61 | -- | 10.32 | -- |
| RetinalGenix Technologies Inc | 0.00 | -4.04m | 62.99m | 0.00 | -- | -- | -- | -- | -0.2291 | -0.2291 | 0.00 | -0.101 | 0.00 | -- | -- | -- | -9,059.05 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -1,050.46 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
| VolitionRX Ltd | 976.52k | -32.42m | 63.89m | 110.00 | -- | -- | -- | 65.43 | -0.4032 | -0.4032 | 0.0121 | -0.263 | 0.0481 | -- | 5.38 | 8,877.45 | -161.39 | -111.92 | -- | -196.20 | -- | -- | -3,357.34 | -10,793.31 | -- | -129.66 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
| Atara Biotherapeutics Inc | 62.39m | -181.05m | 64.05m | 165.00 | -- | -- | -- | 1.03 | -39.90 | -39.90 | 13.06 | -22.61 | 0.343 | 0.931 | 42.60 | 277,275.60 | -99.55 | -70.20 | -256.98 | -86.94 | 80.14 | -- | -290.20 | -1,559.33 | 0.2945 | -250.76 | -- | -- | -86.51 | -- | -20.95 | -- | -49.14 | -- |
| Prelude Therapeutics Inc | 3.00m | -131.52m | 65.49m | 128.00 | -- | 0.3209 | -- | 21.83 | -1.77 | -1.77 | 0.0404 | 3.71 | 0.0132 | -- | -- | 23,437.50 | -57.72 | -47.21 | -63.14 | -51.07 | -- | -- | -4,383.90 | -- | -- | -- | 0.0023 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
| Vor Biopharma Inc | 0.00 | -118.09m | 65.53m | 168.00 | -- | 0.6677 | -- | -- | -1.74 | -1.74 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -60.16 | -45.79 | -64.52 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
| Maia Biotechnology Inc | 0.00 | -28.08m | 69.57m | 13.00 | -- | 21.85 | -- | -- | -1.62 | -1.62 | 0.00 | 0.1332 | 0.00 | -- | -- | 0.00 | -251.96 | -- | -362.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.91 | -- | -- | -- |
| Syros Pharmaceuticals Inc | 386.00k | -97.82m | 70.03m | 68.00 | -- | -- | -- | 181.43 | -3.03 | -3.03 | 0.0105 | -0.4145 | 0.0033 | -- | -- | 5,676.47 | -84.04 | -54.44 | -111.15 | -64.32 | -- | -- | -25,340.67 | -772.82 | -- | -179.01 | 1.37 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
Data as of Nov 08 2024. Currency figures normalised to Prelude Therapeutics Inc's reporting currency: US Dollar USD
35.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 30 Jun 2024 | 10.12m | 24.01% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 999.50k | 2.37% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 895.49k | 2.12% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Jun 2024 | 874.46k | 2.07% |
| Massachusetts Financial Services Co.as of 30 Jun 2024 | 522.38k | 1.24% |
| Geode Capital Management LLCas of 30 Jun 2024 | 361.95k | 0.86% |
| Sio Capital Management LLCas of 30 Jun 2024 | 320.39k | 0.76% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024 | 242.73k | 0.58% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 211.75k | 0.50% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 206.60k | 0.49% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
